Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 353.65M | 336.01M | 335.88M | 487.81M | 410.67M |
Gross Profit | 202.33M | 200.34M | 165.33M | 281.80M | 217.22M |
EBITDA | -65.50M | 22.91M | 15.09M | 85.23M | 41.57M |
Net Income | -103.61M | -15.11M | -30.47M | 35.26M | 7.76M |
Balance Sheet | |||||
Total Assets | 772.93M | 882.58M | 883.53M | 937.16M | 840.77M |
Cash, Cash Equivalents and Short-Term Investments | 116.51M | 166.81M | 168.61M | 197.08M | 165.61M |
Total Debt | 212.13M | 186.29M | 143.48M | 129.07M | 75.02M |
Total Liabilities | 325.34M | 308.06M | 286.07M | 279.24M | 229.54M |
Stockholders Equity | 447.59M | 574.52M | 597.46M | 657.92M | 611.23M |
Cash Flow | |||||
Free Cash Flow | -54.96M | -47.39M | -35.98M | 4.67M | -43.77M |
Operating Cash Flow | -13.75M | 21.72M | 8.33M | 42.78M | 30.09M |
Investing Cash Flow | -40.17M | -67.61M | -43.98M | -31.21M | -50.63M |
Financing Cash Flow | 15.34M | 42.63M | 18.10M | 14.31M | 29.85M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | HK$31.01B | 35.31 | 37.28% | 2.18% | 59.83% | 68.29% | |
68 Neutral | HK$502.25M | 3.91 | 24.41% | 5.38% | 22.46% | 91.73% | |
64 Neutral | HK$842.47M | 12.12 | 8.96% | ― | 30.72% | -35.61% | |
61 Neutral | HK$461.19M | 11.23 | 5.25% | 5.82% | -23.89% | ― | |
61 Neutral | HK$21.08B | 12.39 | 0.81% | 4.52% | 2.72% | -47.45% | |
48 Neutral | HK$1.04B | ― | -20.26% | ― | 5.25% | -581.58% | |
48 Neutral | HK$24.21B | ― | -7.87% | 2.49% | 16.82% | -348.71% |
Natural Beauty Bio-Technology Limited has announced a board meeting scheduled for August 5, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the payment of an interim dividend, which could impact shareholder returns and market perception of the company’s financial health.
Natural Beauty Bio-Technology Limited announced a significant financial turnaround for the first half of 2025, with expected revenues of approximately HK$270 million, marking a 72% increase from the previous year. This growth is attributed to the company’s strategic expansion in the Mainland China market and improved operational efficiencies, leading to a projected net profit of HK$10 million, compared to a net loss in the same period last year.
Natural Beauty Bio-Technology Limited held its Annual General Meeting on May 22, 2025, where all proposed resolutions were unanimously passed. These resolutions included the approval of financial statements, re-election of directors, and granting mandates for share repurchase and issuance, indicating strong shareholder support and strategic flexibility for the company.